Continuum Health Parnters

Add to Favorites

Physicians & Surgeons, Clinics, Physicians & Surgeons, Allergy & Immunology

Be the first to review!

Add Hours

24 Years

in Business

(212) 258-5960Visit WebsiteMap & Directions200 W 57th StNew York, NY 10019 Write a Review

Is this your business?

Customize this page.

Claim This Business

Hours

Do you know the hours for this business?

Continuum Health Parnters

General Practitioners

Medical Weight Loss
Powered by Omega’s recently opened Health Canada and U.S. FDA approved injectable manufacturing facility and strengthened by Juno’s robust commercial network and product development pipeline, Juno will quickly bring an expanded array of critical pharmaceutical products to life and into the hands of medical practitioners and patients. Over the next four years, Juno expects to bring over 100 new products to the Canadian market with key expansions in pain management, oral solutions, allergy vaccines, diabetes & weight-loss and in addition, launch unique offerings in the dental, cosmetic, and animal health sectors.

View All Services

Provided by

Places Near New York with Physicians & Surgeons

Long Island City (4 miles)
Astoria (4 miles)
Hoboken (5 miles)
Jackson Heights (8 miles)
Jersey City (9 miles)
Forest Hills (12 miles)
Brooklyn (13 miles)
Flushing (14 miles)
Bronx (14 miles)
Hackensack (14 miles)

Accepted Insurance

Continuum Health Parnters has not yet specified accepted insurance plans.

Specialties

Continuum Health Parnters has not yet specified any specialties.

More Info

Extra Phones

Phone: (212) 582-2949

Phone: (212) 713-1630

Phone: (212) 664-0359

Services/Products

Medical Services.

Neighborhoods

Theater District, Midtown Manhattan

AKA

Continuum Health Partners

Continuum Heatlh Parnters

Other Link

http://www.signethealthcarepartners.com

Categories

Other Information

Services: Medical Services

Gallery

Be the first to add a photo!

Reviews

Hi there!
Be the first to review!

Click to Rate

Details

Phone: (212) 258-5960

Address: 200 W 57th St, New York, NY 10019

Website: http://www.signethealthcarepartners.com

People Also Viewed

View similar Physicians & Surgeons

Suggest an Edit

Continuum Health Parnters

General Practitioners

Medical Weight Loss
Powered by Omega’s recently opened Health Canada and U.S. FDA approved injectable manufacturing facility and strengthened by Juno’s robust commercial network and product development pipeline, Juno will quickly bring an expanded array of critical pharmaceutical products to life and into the hands of medical practitioners and patients. Over the next four years, Juno expects to bring over 100 new products to the Canadian market with key expansions in pain management, oral solutions, allergy vaccines, diabetes & weight-loss and in addition, launch unique offerings in the dental, cosmetic, and animal health sectors.
Colonoscopy
SMART's G-EYE® Colonoscope, incorporating the G-EYE® Balloon Technology which helps control the endoscope's field of view and positioning during colonoscopy, was cleared for marketing in the USA by FDA
Infectious Diseases
Immunizations
In preclinical studies conducted in collaboration with the University of Alabama at Birmingham (UAB), AdCOVID stimulated both strong serum neutralizing activity and potent mucosal immunity (IgA) in the respiratory tract. Additionally, vaccination of mice with AdCOVID caused the rapid recruitment of immune cells into the respiratory tract, draining lymph nodes and spleen consistent with induction of potent local and systemic immunity. Increases in CD8+ and CD4+ T cells, dendritic cells and NK cells were observed in the respiratory tract, and germinal center and memory B cells as well as T follicular helper cells were observed in regional lymph nodes and the spleen. Importantly, the latter cell types have been associated in prior vaccine development research with long-lived antibody responses.

Ophthalmologists

Glaucoma
EyePoint Pharmaceuticals (formerly pSivida Corp.) ( www.eyepointpharma.com ), headquartered in Watertown, MA, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. In addition, DEXYCU™ was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. DEXYCU is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation and it is the first and only FDA approved intraocular product with this indication. ILUVIEN®(fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert ® (fluocinolone acetonide intravitreal implant), for posterior uveitis, is licensed to and sold by Bausch & Lomb. The New Drug Application (NDA) for our lead product candidate, Durasert™ micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye, has been accepted for filing by the FDA and is currently under standard review with a Prescription Drug User Fee Act (PDUFA) date of November 5, 2018. The Company's pre-clinical development program is focused on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter, LinkedIn, Facebook and Google+.
Ophthalmology
Ophthalmology represents a large and growing therapeutic category with a sizable market, favorable demographics due to an aging population, and significant unmet clinical needs.
Macular Degeneration
Cataracts
On February 9, 2018, the FDA approved Icon Bioscience's New Drug Application (NDA) for DEXYCU, a dropless, long-acting therapeutic for the treatment of postoperative inflammation. There are over four million cataract surgeries performed annually in the U.S. pSivida plans to launch DEXYCU in the U.S. in the first half of 2019 following the successful scale up of commercial supplies.
Cataract Surgery
Icon Bioscience Inc. was previously a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® extended-release drug delivery technology. On February 9, 2018, the United States Food and Drug Administration (FDA) approved Icon Bioscience's New Drug Application (NDA) for DEXYCU™ (dexamethasone intraocular suspension) 9%, a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery. DEXYCU is the first long-acting intraocular product approved by the FDA to treat post-surgical inflammation. Cataract surgery is the most frequent surgical procedure performed in the U.S., with over four million procedures annually. Under current standard of care for inflammation associated with this surgery, patients assume the post-surgical responsibility of self-administering medicated eye drops, several times daily for up to 4 weeks. DEXYCU breaks new ground in the post-surgical treatment of inflammation because it is applied as a single injection at the conclusion of surgery. For additional information visit the Icon website at www.iconbioscience.com.

Gynecology
ABOUT LABORIE MEDICAL TECHNOLOGIES Globally headquartered in Boston, Massachusetts, LABORIE is a leading global developer, manufacturer and marketer of diverse, innovative medical technology used in the diagnosis and treatment of disorders in the Urology, Gynecology, Colorectal, and Gastrointestinal fields. With its recent acquisition of Clinical Innovations, LABORIE is also a leader in medical technology developed for Labor and Delivery and Neonatal Intensive Care. LABORIE is a portfolio company of Patricia Industries. For more information visit www.laborie.com.
Obstetrics
Headquartered in Portsmouth, New Hampshire, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class Clinical Education & Information program. Laborie is a portfolio company of Patricia Industries. For more information visit
Labor and Delivery

Gastroenterology
As part of the transaction, GI Supply and all its employees will be fully integrated into the Laborie business. "We've had the opportunity to work closely with the GI Supply team for two years and are delighted to welcome them into the Laborie family," said Michael Frazzette, President & CEO of Laborie Medical Technologies. "We look forward to working together in our mission to deliver innovative technologies that help preserve and restore human dignity. Gastroenterology will continue to be a core segment for Laborie and legacy GI Supply will lead our effort."
Urology
Nephrology
Claris Injectables manufactures and/or markets a broad portfolio of essential medicines across multiple delivery systems and segments, including anesthesia and analgesics; blood products; anti-infectives; critical care and nephrology. Its manufacturing facilities are registered with global regulatory agencies including the FDA and authorities in the UK, Australia, Brazil and Middle East. Claris Injectables products are sold in more than 75 markets around the world, with direct sales in the United States and India.
Colon Cancer
The G-EYE® Colonoscope is a 510(k) cleared colonoscope, remanufactured by SMART to include a proprietary balloon at its distal bending section. SMART's FDA cleared G-EYE® Colonoscopes include selected models of the leading endoscope brands – Fujifilm, Olympus, and Pentax. Withdrawal of the G-EYE® Colonoscope with the balloon moderately inflated during colonoscopy, assists in controlling the colonoscope's field of view and positioning. In published clinical studies, G-EYE® colonoscopy demonstrated substantial increase over standard colonoscopy in the detection of pre-cancerous polyps which are the precursors of colon cancer (GIE 2019; 89: 545-553; and Endoscopy 2015; 47: 238–244).
Endoscopy
RA'ANANA, Israel, Feb. 16, 2021 /CNW/ -- SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, announced the initiation of commercial and clinical effort in the USA, following issuance of a second FDA clearance for its flagship G-EYE® Colonoscope, based on Fujifilm's 510(k) cleared colonoscopes.

Endocrinologist

Diabetes Care
Endocrinology

Radiation Therapy

Reconstructive Surgery
Innovative product portfolio based on TELA Bio's proven technology platform advances the design of biologic-based materials for reconstructive surgery.

Plastic Surgeons

Breast Reconstruction
TELA Bio’s OviTex Reinforced BioScaffold (RBS) products are a distinct class of surgical implants that integrate biologic and synthetic materials in a unique embroidered construction that allows free movement of fluid and cells through the construct. OviTex RBS products have been used in over 1,000 implantations across a wide range of hernia patients using a variety of surgical techniques. Surgeons report ease of placement, permeability and handling properties, such as suppleness and conformity to the surgical site, as key benefits. TELA Bio has exclusive commercial rights to OviTex for hernia repair and abdominal wall and breast reconstruction procedures in the U.S. and European markets.

Dermatology
Mr. Kapfer continued, "Our newly-acquired brands provide an excellent foundation for us to build upon. We see a clear opportunity to build the Advantice product portfolio in OTC therapeutic skin care. Our work in prescription-based dermatology products and high-end cosmetic skin care provides us with the experience and expertise needed to add value to this business. This value creation orientation has been a long-standing strategic requirement for us."
Skin Care

Allergies

View All Services

Provided by